A5062159874- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Cytokine Signaling Pathways and Interactions
- Medical Imaging Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Cancer therapeutics and mechanisms
- Cancer, Hypoxia, and Metabolism
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- Biochemical and Molecular Research
- Immune cells in cancer
- interferon and immune responses
- Hepatocellular Carcinoma Treatment and Prognosis
- Phagocytosis and Immune Regulation
- Nutrition, Health and Food Behavior
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Inflammasome and immune disorders
- Peptidase Inhibition and Analysis
- Genetic factors in colorectal cancer
- Nutrition and Health in Aging
- Cervical Cancer and HPV Research
Yonsei University
2014-2025
Severance Hospital
2018-2021
Konkuk University
2021
MET amplification is a frequent mechanism of resistance to EGFR tyrosine kinase inhibitors (TKI) in patients with EGFR-mutated non-small cell lung cancer (NSCLC), and combined treatment TKIs has been explored as strategy overcome resistance. However, durable response invariably limited by the emergence acquired Here, we investigated preclinical activity REGN5093-M114, novel antibody-drug conjugate targeting MET-driven patient-derived models.
Abstract Purpose: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) serve as the standard first-line therapy for EGFR-mutated non-small cell lung cancer (NSCLC). Despite sustained clinical benefits achieved through optimal EGFR-TKI treatments, including third-generation osimertinib, resistance inevitably develops. Currently, there are no targeted therapeutic options available postprogression on osimertinib. Here, we assessed preclinical efficacy of BI-4732, a novel...
Ninjurin1 is a homotypic adhesion molecule that contributes to leukocyte trafficking in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. However, vivo gene deficiency studies have not yet been done. Here, we constructed knock-out (KO) mice and investigated the role on under inflammation conditions such as EAE endotoxin-induced uveitis. KO attenuated susceptibility by reducing recruitment into injury regions spinal cord showed less leukocytes inflamed...
Natural killer (NK) cells have recently shown renewed promise as therapeutic for use in treating hematologic cancer indications. Despite this promise, NK cell manufacturing workflows remain largely manual, open, and disconnected, depend on feeders, well outdated unit operations or processes, often utilizing research-grade reagents. Successful scale-up of critically depends the availability performance nutrient-rich expansion media cryopreservation conditions that are conducive to high...
Introduction: Despite the availability of several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), most patients with non-small-cell lung cancer (NSCLC) eventually develop resistance to these agents. Notably, EGFR_C797S mutations confer third-generation EGFR-TKI osimertinib and no approved post-osimertinib targeted pharmacology options are currently available. BLU-945 is a novel, reversible, orally available next-generation that selectively targets EGFR-activating (...
Glutamine-addicted cancer metabolism is recently recognized as novel target especially for KRAS and KEAP1 co-occurring mutations. Selective glutaminase1 (GLS1) inhibition was reported using BPTES which has mode of allosteric inhibition. However, a highly hydrophobic symmetric molecule with very poor solubility results in suboptimal pharmacokinetic parameters hinders its further development. As an ongoing effort to identify more drug-like GLS1 inhibitors via systematic structure − activity...
A recently developed treatment strategy for lung cancer that combines immune checkpoint inhibitors with chemotherapy has been applied as a standard adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), it improved the outcomes of chemotherapy. Maintenance anti-PD-1 antibody (aPD-1) enhances effect immunochemical combination therapy improves therapeutic efficacy, which contributes toward significant improvement in patient survival rates. The AXL receptor tyrosine kinase (AXL), is...
Agonists of the stimulator interferon genes (STING) play a key role in activating STING pathway by promoting production cytokines. In this study, we investigated antitumor effects and activation systemic immune response treatment with DMXAA (5,6-dimethylxanthenone-4-acetic acid), agonist, EML4-ALK lung cancer CT26 colon cancer.
Vascular regeneration plays a critical role in the treatment of cardiovascular diseases and tissue engineering applications. In this study, we fabricated characterized statin/curcumin-loaded nanoparticles for potential applications vascular regeneration. The exhibited consistent spherical shape sizes, indicating reproducibility stability fabrication process. sustained release loaded drugs from indicated their suitability controlled prolonged drug delivery. Biocompatibility assessments...
AXL-mediated activation of aberrant tyrosine kinase drives various oncogenic processes and facilitates an immunosuppressive microenvironment. We evaluated the anti-tumor anti-metastatic activities SKI-G-801, a small-molecule inhibitor AXL, alone in combination with anti-PD-1 therapy.In vitro pAXL inhibition by SKI-G-801 was performed both human mouse cancer cell lines. Immunocompetent models tumor were established to measure potential SKI-G-801. Furthermore, or their administered as adjuvant...
Immune checkpoint inhibitors (ICIs), including programmed cell death protein 1 (PD-1)/programmed death-ligand (PD-L1) and cytotoxic T-lymphocyte-associated 4 have shown promising cancer clinical outcomes. However, IC therapy has low patient response rates (10%–15%). Thus, ICIs sufficient antigen combinations into the tumor microenvironment (TME) is important to produce strong tumor-specific adaptive immune responses. Mice were treated with cisplatin, human cells exposed inflammatory...
Abstract Introduction: Although the use of immune checkpoint inhibitors (ICIs) has improved survival rate some patients, EGFR mutant (MT) NSCLC patients exhibit a poor response to ICIs compared wild-type (WT) patients. It been demonstrated that MT cells contribute immunosuppressive tumor microenvironments (TMEs) by secreting inhibitory cytokines and metabolites recruiting pro-tumor immunogenic cells, thereby diminishing ICI efficacy. In particular, myeloid represent major component TME are...
<div>AbstractPurpose:<p>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) serve as the standard first-line therapy for EGFR-mutated non-small cell lung cancer (NSCLC). Despite sustained clinical benefits achieved through optimal EGFR-TKI treatments, including third-generation osimertinib, resistance inevitably develops. Currently, there are no targeted therapeutic options available postprogression on osimertinib. Here, we assessed preclinical efficacy of...
<p>In vitro activity of BI-4732 against Ba/F3 cells expressing EGFR-activating mutations and T790M mutation</p>
<p>In vitro activity of BI-4732 in PDC cells harboring EGFR-activating mutations and T790M mutation</p>
<p>In vitro activity of BI-4732 against Ba/F3 cells expressing EGFR-activating mutations and T790M mutation</p>
<p>Antitumor efficacy of BI-4732 in PC9-driven intracranial tumor models</p>
<p>In vitro activity of BI-4732 in PDC cells harboring EGFR-activating mutations and T790M mutation</p>
<div>AbstractPurpose:<p>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) serve as the standard first-line therapy for EGFR-mutated non-small cell lung cancer (NSCLC). Despite sustained clinical benefits achieved through optimal EGFR-TKI treatments, including third-generation osimertinib, resistance inevitably develops. Currently, there are no targeted therapeutic options available postprogression on osimertinib. Here, we assessed preclinical efficacy of...
<p>Antitumor efficacy of BI-4732 in PC9-driven intracranial tumor models</p>